Elan Corporation, plc (NYSE: ELN) and Wyeth (NYSE: WYE) announced that the companies will discontinue the highest of three dosing regimens, 2.0 mg/kg, in the two ongoing Phase 3 studies of bapineuzumab in clientele with mild to modest Alzheimer's disease (AD) who do not carry the Apolipoprotein E4 (ApoE4) allele (non-carriers). ApoE4 is a known genetic risk factor for evolvement of AD. The 0.

More: - Brought to my attention by